Estados Unidos · Bolsa y Finanzas · Yahoo Finance

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

Publicado por Yahoo Finance · Estados Unidos hace 1 d

Takeda (TSE:4502/NYSE:TAK) announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to…

Leer el artículo completo en Yahoo Finance Inicie sesión para guardar

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (finance.yahoo.com)

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

También te puede interesar

ByteDance's short-drama app is turning into China's latest obsession

Collective Metals announces $515K non-brokered private placement

Oil Prices Head for Weekly Gain as Hormuz Attacks Rattle Markets

Even Benchmark thinks AI is eroding the venture pact against backing rivals

Balaji’s ‘Singapore of social media’ begins with a wave of bans

Fed's Warsh withholds Fed rate signal, praises recent global tightening with 'no free riders'

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

Compartir

También te puede interesar

ByteDance's short-drama app is turning into China's latest obsession

Collective Metals announces $515K non-brokered private placement

Oil Prices Head for Weekly Gain as Hormuz Attacks Rattle Markets

Even Benchmark thinks AI is eroding the venture pact against backing rivals

Balaji’s ‘Singapore of social media’ begins with a wave of bans

Fed's Warsh withholds Fed rate signal, praises recent global tightening with 'no free riders'